Rajesh Rajpal, MD
Ophthalmology · Mc Lean, VANPI 1790887800
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,875 of the $59,752 with a category attached, or 68.4%. 21 manufacturers reported payments, led by Alcon at 26.9% of the total. Reporting peaked in 2019 at $31,554 and has fallen 55.4% since, to $14,063 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $459.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$16K
- AbbVie$15K
- Glaukos Corporation$13K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Eyepoint US, Inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- plus $1K from 15 others
What the payments were for
- Consulting fees$40,87568%
- Speaking & faculty fees$12,12020%
- Travel & lodging$2,0023%
- Food & beverage$4,7558%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $16,065 |
| AbbVie(2 entities) | 49 | $14,767 |
| Glaukos Corporation | 14 | $12,781 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $9,972 |
| Eyepoint US, Inc. | 6 | $2,559 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,488 |
| Dompe US, Inc. | 2 | $228 |
| Kala Pharmaceuticals, Inc. | 4 | $204 |
| Bausch & Lomb Americas Inc. | 2 | $178 |
| Sun Pharmaceutical Industries Inc. | 4 | $136 |
| Carl Zeiss Meditec, Inc. | 2 | $83 |
| Alcon Research LLC | 1 | $57 |
| Eyevance Pharmaceuticals LLC | 1 | $37 |
| Sight Sciences, Inc. | 2 | $37 |
| Omeros Corporation | 2 | $33 |
| Lensar, Inc. | 1 | $27 |
| Rxsight Inc | 1 | $23 |
| Harrow Eye, LLC | 1 | $21 |
| Novartis | 1 | $21 |
| Osmotica Pharmaceutical Corp. | 1 | $19 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOTEMAX SM$9,404
- DAILIES$9,100
- Systane$6,300
- AcrySof IQ VIVITY IOL$6,300
- KXL System$5,350
- Epioxa$5,250
- RESTASIS$5,208
- DEXYCU$2,400
- Travoprost Intraocular Implant - iDose$1,560
- PROLENSA$1,324
- VYZULTA$1,220
- ALREX$1,220
- BEPREVE$1,220
- Photrexa Viscous and Photrexa$243
- Oxervate$228
- iAccess Precision Blade$158
- INVELTYS$125
- DURYSTA$120
- ReSTOR$120
How this compares
$59,752 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 18 | $27,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $14,767 | $27,70618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Mc Lean
- Kim JiramongkolchaiMc Lean$11K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Leonard RappaportPortsmouth$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.